3-二甲基氨基-1-(3-噻吩)-1-丙酮 | 100860-96-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-二甲基氨基-1-(3-噻吩)-1-丙酮
• 英文名称: 3-(dimethylamino)-1-(thiophen-3-yl)propan-1-one
• 英文别名: 3-(dimethylamino)-1-thiophen-3-ylpropan-1-one
• CAS: 100860-96-6
• 化学式: C₉H₁₃NOS
• 分子量: 183.274
• InChiKey: DYYOWHYLIHNOQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  273.3±20.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-二甲基氨基-1-(3-噻吩)-1-丙酮 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 甲醇 为溶剂， 生成 (S)-N,N-二甲基-3-羟基-3-(2-噻吩基)丙胺
  参考文献：
  名称：

  Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake

  摘要：

  A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. One member of this series, duloxetine (Cymbalta(TM)) has proven to be effective in clinical trials for the treatment of depression. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.079
• 作为产物：
  描述：

  3-乙酰基噻吩 、 聚合甲醛 、 盐酸二甲胺 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-二甲基氨基-1-(3-噻吩)-1-丙酮
  参考文献：
  名称：

  Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake

  摘要：

  A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. One member of this series, duloxetine (Cymbalta(TM)) has proven to be effective in clinical trials for the treatment of depression. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.079

文献信息

• Process for Pure Duloxetine Hydrochloride
  申请人：Reddy Manne Satyanarayana

  公开号：US20090012315A1

  公开（公告）日：2009-01-08

  A process for the preparation of pure Duloxetine hydrochloride comprises the steps of: a) reacting 1-(thiophen-2-yl)ethanone with dimethylamine hydrochloride, b) purifying the component in a solvent, c) reducing the component with an alkali metal borohydride, d) resolving the compound with a chiral acid, and treating the obtained compound with weak inorganic base, e) reacting the compound to give Duloxetine oxalate salt and f) converting the Duloxetine salt into its hydrochloride salt. Further the purifications of the obtained compound and of two intermediate products are described.

  制备纯度杜氯西泮盐酸盐的过程包括以下步骤：a）将1-（噻吩-2-基）乙酮与盐酸二甲胺反应，b）在溶剂中纯化组分，c）用碱金属硼氢化物还原组分，d）用手性酸分离化合物，并用弱无机碱处理所得化合物，e）反应化合物得到杜氯西泮草酸盐，f）将杜氯西泮草酸盐转化为其盐酸盐。此外，还描述了所得化合物和两个中间产物的纯化过程。
• OGATA, MASARU;MATSUMOTO, HIROSHI;KIDA, SHIRO;SHIMIZU, SUMIO;TAWARA, KATSU+, J. MED. CHEM., 30,(1987) N 8, 1497-1502
  作者：OGATA, MASARU、MATSUMOTO, HIROSHI、KIDA, SHIRO、SHIMIZU, SUMIO、TAWARA, KATSU+

  DOI：——

  日期：——
• US8362279B2
  申请人：——

  公开号：US8362279B2

  公开（公告）日：2013-01-29
• [EN] IMPROVED PROCESS FOR PURE DULOXETINE HYDROCHLORIDE<br/>[FR] PROCEDE AMELIORE POUR LA PREPARATION DE CHLORHYDRATE DE DULOXETINE
  申请人：MSN LAB LTD

  公开号：WO2007077580A2

  公开（公告）日：2007-07-12

  [EN] A process for the preparation of pure Duloxetine hydrochloride comprises the steps of : a) reacting 1-(thiophen-2-yl)ethanone with dimethylamine hydrochloride, b) purifying the component in a solvent, c) reducing the component with an alkali metal borohydride, d) resolving the compound with a chiral acid, and treating the obtained compound with weak inorganic base, e) reacting the compound to give Duloxetine oxalate salt and f) converting the Duloxetine salt into its hydrochloride salt. Further the purifications of the obtained compound and of two intermediate products are described.
  [FR] La présente invention concerne un procédé amélioré pour la préparation de composé de chlorhydrate de duloxétine comprenant les étapes suivantes: a) la réaction de 1-(thiophen-2-yl)éthanone avec du chlorhydrate de diméthylamine, b) la purification du constituant dans un solvant, c) la réduction du constituant avec un borohydrure de métal alcalin, d) la résolution du composé avec un acide chiral, et le traitement du composé obtenu avec une base organique faible, e) la réaction du composé pour obtenir du sel oxalate de duloxétine, et f) la conversion du sel de duloxétine en son sel de chlorhydrate. L'invention concerne également les procédés de purifications du composé obtenu et de deux produits intermédiaires.
• Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities
  作者：Jong-Keun Son、Long-Xuan Zhao、Arjun Basnet、Pritam Thapa、Radha Karki、Younghwa Na、Yurngdong Jahng、Tae Cheon Jeong、Byeong-Seon Jeong、Chong-Soon Lee、Eung-Seok Lee

  DOI：10.1016/j.ejmech.2007.05.002

  日期：2008.4

  For the development of novel antitumor agents, we designed and synthesized 2,6-diaryl-substituted pyridine derivatives bearing three aryl groups, which are the bioisosteres of terpyridine, and evaluated their biological activities. Most of the 18 prepared compounds showed moderate cytotoxicity against several human cancer cell lines. From the structure-activity relationships we may conclude that the number of aryl groups employed would be critical for their biological activities. (c) 2007 Elsevier Masson SAS. All rights reserved.